[Correspondence] Olanzapine for chemotherapy-induced nausea and vomiting control

April, 04, 2024 | Select Oncology Journal Articles

In The Lancet Oncology, Jyoti Bajpai and colleagues1 reported that olanzapine 2·5 mg should be considered as a new standard of care for antiemetic agents in patients receiving highly emetogenic chemotherapy.

For Additional News from OncWeekly – Your Front Row Seat To The Future of Cancer Care –




Sign up for our emails

Trusted insights straight to your inbox and get the latest updates from OncWeekly

Privacy Policy